Cambridge Investment Research Advisors Inc. Decreases Stock Holdings in Dynavax Technologies Co. (NASDAQ:DVAX)

Cambridge Investment Research Advisors Inc. trimmed its stake in shares of Dynavax Technologies Co. (NASDAQ:DVAXGet Rating) by 7.3% in the 3rd quarter, Holdings Channel reports. The firm owned 13,125 shares of the biopharmaceutical company’s stock after selling 1,035 shares during the period. Cambridge Investment Research Advisors Inc.’s holdings in Dynavax Technologies were worth $137,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. Advisors Asset Management Inc. grew its position in Dynavax Technologies by 498.0% during the first quarter. Advisors Asset Management Inc. now owns 2,362 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 1,967 shares during the period. Quantbot Technologies LP grew its position in Dynavax Technologies by 940.7% during the first quarter. Quantbot Technologies LP now owns 2,508 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 2,267 shares during the period. Banque Cantonale Vaudoise bought a new stake in Dynavax Technologies during the second quarter valued at approximately $67,000. Point72 Hong Kong Ltd bought a new stake in Dynavax Technologies during the first quarter valued at approximately $102,000. Finally, Captrust Financial Advisors grew its position in Dynavax Technologies by 1,116.0% during the second quarter. Captrust Financial Advisors now owns 10,336 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 9,486 shares during the period. 94.26% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on DVAX. The Goldman Sachs Group cut their target price on shares of Dynavax Technologies from $24.00 to $21.00 and set a “buy” rating for the company in a research report on Friday, November 4th. JMP Securities initiated coverage on shares of Dynavax Technologies in a research report on Tuesday, September 27th. They issued an “outperform” rating and a $22.00 price target for the company. Finally, StockNews.com lowered shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research report on Monday, November 7th.

Dynavax Technologies Stock Performance

DVAX opened at $11.35 on Tuesday. The firm has a market cap of $1.45 billion, a P/E ratio of 5.48 and a beta of 1.37. Dynavax Technologies Co. has a 1-year low of $7.26 and a 1-year high of $17.48. The company has a 50 day simple moving average of $11.64 and a two-hundred day simple moving average of $12.20. The company has a debt-to-equity ratio of 0.44, a current ratio of 3.82 and a quick ratio of 3.40.

Dynavax Technologies (NASDAQ:DVAXGet Rating) last issued its earnings results on Thursday, November 3rd. The biopharmaceutical company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.33 by $0.10. Dynavax Technologies had a net margin of 44.35% and a return on equity of 90.54%. The firm had revenue of $167.74 million during the quarter, compared to analyst estimates of $149.99 million. Equities analysts forecast that Dynavax Technologies Co. will post 1.93 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Andrew A. F. Hack sold 1,500,000 shares of the company’s stock in a transaction on Tuesday, December 6th. The shares were sold at an average price of $11.60, for a total transaction of $17,400,000.00. Following the completion of the transaction, the director now owns 3,915,000 shares in the company, valued at $45,414,000. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, Director Andrew A. F. Hack sold 1,500,000 shares of the company’s stock in a transaction on Tuesday, December 6th. The shares were sold at an average price of $11.60, for a total transaction of $17,400,000.00. Following the sale, the director now owns 3,915,000 shares of the company’s stock, valued at $45,414,000. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, COO David F. Novack sold 52,204 shares of the company’s stock in a transaction on Tuesday, November 8th. The shares were sold at an average price of $12.47, for a total transaction of $650,983.88. Following the sale, the chief operating officer now directly owns 2,066 shares in the company, valued at approximately $25,763.02. The disclosure for this sale can be found here. 9.31% of the stock is owned by company insiders.

Dynavax Technologies Profile

(Get Rating)

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.

Further Reading

Want to see what other hedge funds are holding DVAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dynavax Technologies Co. (NASDAQ:DVAXGet Rating).

Institutional Ownership by Quarter for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.